Artelo Biosciences, Inc. (ARTL )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol ARTL
- Company Artelo Biosciences, Inc.
- Price $10.54
- Changes Percentage 230.41
- Change 7.35
- Day Low $7.45
- Day High $19.9
- Year High $85.8
- Year Low $3.15
- Market Cap $22,395,097
- Price Avg 50 EMA (D) $4.48
- Price Avg 200 EMA (D) $15.34
- Exchange NASDAQ
- Volume 81,793,627
- Average Volume 1,247,503
- Open $7.99
- Previous Close $3.19
- EPS -37.56
- PE -0.28
- Earnings Announcement 2026-05-19 12:00:00
- Shares Outstanding $2,124,772
Company brief: ARTELO BIOSCIENCES, INC. (ARTL )
- Healthcare
- Biotechnology
- Mr. Gregory D. Gorgas M.B.A.
- https://www.artelobio.com
- US
- N/A
- 06-21-2019
- US04301G5080
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. Artelo Biosciences, Inc. has research collaboration with Trinity College Dublin to investigate ART27.13 for the treatment of cancer cachexia. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.
ARTL Corporation News
Artelo Biosciences, Inc. (NASDAQ:ARTL) Sees Significant Decrease in Short Interest
defenseworld.net -- Artelo Biosciences, Inc. (NASDAQ: ARTL - Get Free Report) saw a large decline in short interest in the month of March. As of March 13th, there was short interest totaling 37,410 shares, a decline of 2...
Artelo Biosciences Stock Soars After Withdrawing SEC Filing
benzinga.com -- Artelo Biosciences requested the withdrawal of its Registration Statement on Form S-1, initially filed with the U.S. Securities and Exchange Commission on March 20 and declared effective on March 25....
Artelo Biosciences Expansion into $16.3B Glaucoma Market, Via Fully Funded Study, Highlights Multi-Platform Pipeline Strength
globenewswire.com -- Three clinical programs, one core molecule, and a capital-efficient strategy position Artelo Biosciences for sustained growth beyond a single indication Three clinical programs, one core molecule, and...